2. Academic Validation
  3. Hydantoin based inhibitors of MMP13--discovery of AZD6605

Hydantoin based inhibitors of MMP13--discovery of AZD6605

  • Bioorg Med Chem Lett. 2013 Aug 15;23(16):4705-12. doi: 10.1016/j.bmcl.2013.05.089.
Chris De Savi 1,  David Waterson,  Andrew Pape,  Scott Lamont,  Elma Hadley,  Mark Mills,  Ken M Page,  Jonathan Bowyer,  Rose A Maciewicz
Affiliations

Affiliation

  • 1 Oncology Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. chris.desavi2@astrazeneca.com
PMID: 23810497 DOI: 10.1016/j.bmcl.2013.05.089
Abstract

Piperidine ether and aryl piperazine hydantoins are reported as potent inhibitors of MMP13. A medicinal chemistry campaign focused on replacing the reverse hydroxamate zinc binding group associated with historical inhibitors with a hydantoin zinc binding group then optimising MMP13 potency, solubility and DMPK properties whilst maintaining good selectivity over MMP14. A number of high quality candidates were progressed and following rat and dog safety evaluation, AZD6605 (3m) was identified as a candidate drug.

Keywords

Cyp P450; Hydantoin; Lead optimisation; MMP13; Zinc binder.

Figures
Products